Barinthus Biotherapeutics plc (BRNS) Financials

BRNS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 81.9 million 24.8 million
March 31, 2026 92.1 million 25.7 million
Dec. 31, 2025 98.2 million 23.9 million
Sept. 30, 2025 109.2 million 24.6 million

BRNS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -8.1 million 433000
March 31, 2026 -3.4 million 556000
Dec. 31, 2025 -4.2 million 696000
Sept. 30, 2025 -10.7 million -415000

BRNS Net Income

No data available :(

BRNS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 59.3 million - 10.3 million
March 31, 2026 67.2 million - 11.0 million
Dec. 31, 2025 70.5 million - 11.3 million
Sept. 30, 2025 74.3 million - 11.6 million

BRNS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 40.8 million
March 31, 2026 40.8 million
Dec. 31, 2025 40.5 million
Sept. 30, 2025 40.7 million

BRNS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 3.9 million 7.1 million -
March 31, 2026 2 3.6 million 2.5 million -
Dec. 31, 2025 50 3.9 million 4.6 million -
Sept. 30, 2025 182 5.2 million 5.2 million -

BRNS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 854565
Dec. 31, 2025 - 907686
Sept. 30, 2025 - -

BRNS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

BRNS

Price: $0.62

52 week price:
0.51
1.83

Earnings Per Share: -1.03 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 23.8 million

Links: